* InspireMD Inc NSPR.OQ NSPR.O is expected to show a
fall in
quarterly revenue when it reports results on March 30.
* The Tel Aviv-yafo Israel-based company is expected to
report
a 27.5% decrease in revenue to $1 million from $1.38 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for InspireMD Inc is
for a
loss of 84 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for InspireMD
Inc is
$5.6, above its last closing price of $1.17.
This summary was machine generated March 3 at 13:50 GMT. All
figures in US dollars unless otherwise stated